European regulators recommend approval of Orexigen’s obesity pill

(Reuters) – European regulators recommended the approval of Orexigen Therapeutics Inc’s diet pill, which could become the first prescription medicine for obesity to be approved in the European Union in nearly a decade. The drug, sold as Contrave by partner Takeda Pharmaceutical Co in the United States, will be marketed as Mysimba in Europe. The European Commission is expected to give its decision on the drug in early 2015, Orexigen said. The treatment, which won U.S. …
Go to Source